Turning Point Therapeutics Announces Appointment of Brian Sun, M.S., J.D., as Incoming General Counsel
March 29 2022 - 9:00AM
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage
precision oncology company developing next-generation therapies
that target genetic drivers of cancer, today announced the
appointment of Brian Sun, M.S., J.D. as its incoming Senior Vice
President and General Counsel, effective as of April 11, 2022.
Mr. Sun currently serves as Senior Vice President and General
Counsel at Sorrento Therapeutics, Inc, a Nasdaq-listed company,
where he leads the legal function and team. Previously, he worked
at Prometheus Laboratories and Hologic and served as outside
general counsel to early-stage biotechnology companies. Earlier in
his career, Mr. Sun worked in private practice at Foley &
Lardner LLP. Mr. Sun holds a J.D. from the University of San Diego,
an M.S. in Biotechnology from Johns Hopkins University, and a B.A.
in Molecular and Cell Biology from the University of California,
Berkeley.
“I am excited to welcome Brian to the team. He will
be instrumental as we continue to work towards our vision to be the
leader in precision oncology,” said Athena Countouriotis, M.D.,
president and CEO. “Brian brings a unique and highly relevant skill
set, with deep experience in biotech, and we look forward to his
leadership of our legal function and his contributions as a member
of the Executive Team.”
About Turning Point Therapeutics
Inc.Turning Point Therapeutics is a clinical-stage
precision oncology company with a pipeline of internally discovered
investigational drugs designed to address key limitations of
existing cancer therapies. The company’s lead drug candidate,
repotrectinib, is a next-generation kinase inhibitor targeting the
ROS1 and TRK oncogenic drivers of non-small cell lung cancer and
advanced solid tumors. Repotrectinib, which is being studied in a
registrational Phase 2 study in adults and a Phase 1/2 study in
pediatric patients, has shown antitumor activity and durable
responses among kinase inhibitor treatment-naïve and pre-treated
patients. The company’s pipeline of drug candidates also includes
elzovantinib, targeting MET, CSF1R and SRC, which is being studied
in a Phase 1 trial of patients with advanced or metastatic solid
tumors harboring genetic alterations in MET; TPX-0046, targeting
RET, which is being studied in a Phase 1/2 trial of patients with
advanced or metastatic solid tumors harboring genetic alterations
in RET; and TPX-0131, a next-generation ALK inhibitor, which is
being studied in a Phase 1/2 trial of previously treated patients
with ALK-positive advanced or metastatic non-small cell lung
cancer. The company is driven to develop therapies that mark a
turning point for patients in their cancer treatment. For more
information, visit www.tptherapeutics.com.
Forward Looking Statements Statements contained
in this press release regarding matters that are not historical
facts are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995 and include
statements regarding Turning Point Therapeutics being a leader in
precision oncology and the potential of Turing Point Therapeutics’
drug candidates. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Words such
as “plans”, “will”, “believes,” “anticipates,” “expects,”
“intends,” “goal,” “potential” and similar expressions are intended
to identify forward-looking statements. These forward-looking
statements are based upon Turning Point Therapeutics’ current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Actual results could differ materially
from those anticipated in such forward-looking statements as a
result of various risks and uncertainties, which include, without
limitation, risks and uncertainties associated with Turning Point
Therapeutics’ business in general, risks and uncertainties related
to the impact of the COVID-19 pandemic to Turning Point
Therapeutics’ business and the other risks described in Turning
Point Therapeutics’ filings with the SEC, including its Form
10-K filed with the Securities and Exchange Commission
(SEC) on February 28, 2022. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. Turning Point
Therapeutics undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
Contact: Adam D. Levy, PhD.,
MBA[ir@tptherapeutics.com]858-876-3985
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Apr 2023 to Apr 2024